| WARF | warfarin [Wisconsin Alumni Research Foundation] |
|---|---|
| WDI | warfarin dose index |
| teratogenicity | <pharmacology> The ability to cause defects in a developing foetus. This is distinct from mutagenicity, which causes genetic mutations in sperms, eggs or other cells. Teratogenicity is a potential side effect of many drugs, such as thalidomide. (09 Oct 1997) |
|---|---|
| warfarin | <drug> Synthetic inhibitor of prothrombin activation and therefore an inhibitor of blood clotting. Also used as a rat poison. (18 Nov 1997) |
| warfarin-7-hydroxylase | <enzyme> Hydroxylates warfarin in presence of cytochrome p-450 and NADPH Registry number: EC 1.14.13.- (26 Jun 1999) |
| warfarin sodium | [[3-(alpha-Acetonylbenzyl)-2-oxo-2H-1-benzopyran-4-yl]oxy]sodium;an anticoagulant with the same actions as dicumarol; also used as a rodenticide; also available as the potassium salt, with the same actions and uses. Origin: Wisconsin Alumni Research Foundation + coumarin (05 Mar 2000) |
| S-warfarin keto reductase | <enzyme> Rat liver microsome enzyme reduces s-warfarin to its 11s-oh product Registry number: EC 1.1.1.- Synonym: warfarin 11-reductase (26 Jun 1999) |
| foetal warfarin syndrome | <obstetrics> Foetal bleeding, nasal hypoplasia, optic atrophy, and foetal death resulting from administration of warfarin to the pregnant patient. (05 Mar 2000) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|